In agreement with these results, an antiplatelet treatment (aspirin-clopidogrel) attenuated steatosis (e.g., reduction of hepatic TG content, serum cholesterol levels and NAFLD Activity Score, NAS), reduced liver damage (decreased alanine aminotransferase (ALT) levels) and abrogated hepatic immune cell infiltration (T lymphocytes and macrophages) in the NASH-murine model [40]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.